

10/577047

APPROPRIATE 24 APR 2006

**PATENT APPLICATION**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of

Docket No: Q94625

Kazuyuki OHMOTO, et al.

Appln. No.: Based on PCT/JP04/016056

Confirmation No.: Unknown

Group Art Unit: Unknown

Filed: April 24, 2006

Examiner: Unknown

For: ANTISTRESS DRUG AND MEDICAL USE THEREOF

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. §§ 1.97 and 1.98**

**MAIL STOP AMENDMENT**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

A copy of an International Search Report in a counterpart application is submitted herewith. The USPTO should receive copies of the references cited in the International Search Report from the International Bureau. Applicant will furnish any missing references upon request.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after

10/577047  
APR 20 2006  
INFORMATION DISCLOSURE STATEMENT  
U.S. Appln. No.: Based on PCT/JP04/016056  
Attorney Docket No.: Q94625


filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents, Applicant encloses herewith a copy of a Communication from a foreign patent office in a counterpart application citing such documents (International Search Report for PCT/JP04/016056 dated December 14, 2004), together with an English-language version (if not already included) of at least that portion of the Communication indicating the degree of relevance found by the foreign patent office.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,



SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

Mark Boland  
Registration No. 32,197

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: April 24, 2006

Substitute for Form 1449 A & B/PTO  <b>INFORMATION DISCLOSURE          STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<i>Complete if Known</i>			
		Application Number	Based on PCT/JP04/016056		
		Confirmation Number	Unknown		
		Filing Date	October 22, 2004		
		First Named Inventor	Kazuyuki OHMOTO		
		Art Unit	Unknown		
		Examiner Name	Unknown		
Sheet	1	of	1	Attorney Docket Number	Q94625

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code <sup>2</sup> (if known)		
		US			

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
		WO	98/14213	A	04-09-1998	Daiichi Pharmaceutical Co., Ltd.	
		WO	03/68753	A1	08-21-2003	Ono Pharmaceutical Co., Ltd.	
		JP	2001-199982	A	07-24-2001	Dainippon Pharmaceutical Co., Ltd.	
		WO	03/82191	A	10-09-2003	MERCK & CO., INC.	
		WO	02/20495	A	03-14-2002	CHIRON CORP.	
		WO	02/92573	A2	11-21-2002	VERTEX PHARMACEUTICALS INC.	
		JP	2003-523380	A	08-05-2003	F. Hoffman-La Roche AG	
		JP	2002-510322	A	04-02-2002	Du Pont Pharmaceuticals Co.	
		WO	02/79197	A	10-10-2002	VERTEX PHARMACEUTICALS INC.	
		WO	03/35639	A1	03-01-2003	Eisai Co., Ltd.	
		WO	02/96421	A1	12/05/2002	NEUROGEN CORP.	
		JP	10-226649	A	08-25-1998	Tanabe Seiyaku Co., Ltd.	
		WO	00/73279	A	12-07-2000	F. Hoffman-La Roche AG	
		JP	2001-525794	A	12-11-2001	F. Hoffman-La Roche AG	
		WO	03/72107	A1	09-04-2003	PHARMACIA & UPJOHN CO.	
		WO	03/45924	A1	06-05-2003	PHARMACIA & UPJOHN CO.	
		JP	11-209350	A	08-03-1999	Eisai Co., Ltd.	
		WO	96/32384	A1	10-17-1996	Taiho Pharmaceutical Co. Ltd.	
		WO	03/29248	A1	04-10-2003	CYCLACEL LIMITED	
		JP	3-7266	A	01-14-1991	Shiratori Pharmaceutical Co., Ltd.	
		JP	6-501926	A	03-03-199	Fujisawa Pharmaceutical Co., Ltd.	
		WO	02/49648	A1	06-27-2002	SCHERING CORP.	
		WO	03/62871	A	08-07-2003	NOVARTIS PHARMA GMBH	

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation <sup>6</sup>
		KATSUNAO TANAKA, et al., "Synthesis of a Magnosalin Derivative, 4-(3,4,5-trimethoxyphenyl)-6-(2,4,5-trimethoxyphenyl)-2-diethylaminopyrimidine, and the Anti-Angiogenic and Anti-Rheumatic Effect of Mice by Oral Administration", Bioorganic & Medicinal Chemistry Letters 12, 2002, pp. 623-627, Vol. 12, No. 4	
		International Search Report for PCT/JP04/016056 dated December 14, 2004	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov), MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to indicate here if English language Translation is attached.